Allt inom Other Corporate Information
Nanexa and Applied Materials terminates collaboration
Nanexa and Applied Materials, Inc. have collaborated since 2020 regarding production equipment to be used for upscaling of the PharmaShell process. The companies have now agreed to terminate the collaboration.
Analysis of the first samples from the 30 mg dose group in the NEX-22 Phase I study shows continued promising results
Nanexa announced today that the first pharmacokinetic (PK) samples from the final dose group, 30 mg, in the ongoing Phase I study for NEX-22 have been analyzed. The results show that the PK profile is similar to that of previous dose groups and that plasma exposure continues to increase with higher doses.